ARTICLE | Company News
Tecentriq could be first front-line SCLC therapy approved in two decades
December 5, 2018 8:50 PM UTC
FDA accepted and granted Priority Review to an sBLA from Genentech Inc. for anti-PD-L1 mAb Tecentriq atezolizumab as first-line treatment of extensive-stage small cell lung cancer. Its PDUFA date is March 18, 2019.
Genentech CMO and Head of Global Product Development Sandra Horning said in a statement that Tecentriq could be the first drug approved in more than 20 years for the indication...
BCIQ Target Profiles